OAT3 CRISPR/Cas9 KO Plasmid (m): sc-422696
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- OAT3 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the OAT3 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: OAT3 Antibody (3C11): sc-293264
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
OAT3 CRISPR/Cas9 KO Plasmid (m) | sc-422696 | 20 µg | $397.00 |
Overview
Slc22a8 encodes organic anion transporter 3 (OAT3), a basolateral polyspecific uptake transporter that mediates cellular import of diverse endogenous metabolites and xenobiotic organic anions. In mouse kidney proximal tubule, OAT3 supports vectorial secretion by coupling uptake from blood to downstream apical efflux transporters, shaping renal clearance and systemic exposure to many small molecules. By influencing organic anion exchange and intracellular metabolite handling, OAT3 contributes to solute homeostasis and intersects with pathways involved in tubular transport, uremic toxin disposition, and nephrotoxicity susceptibility. Altered OAT3 activity has been implicated in kidney injury mechanisms and pharmacokinetic variability, making Slc22a8 a useful locus for modeling transporter-dependent phenotypes.
OAT3 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Slc22a8 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Slc22a8 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Slc22a8 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish OAT3 protein expression.
This CRISPR knockout system enables efficient generation of Slc22a8-deficient cell models for investigation of OAT3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Slc22a8 exon(s) critical for OAT3 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Slc22a8 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by OAT3 CRISPR/Cas9 KO Plasmid (m) and OAT3 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Slc22a8 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by OAT3 HDR Plasmid (m) and OAT3 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Slc22a8 homology arms to support homology-directed repair at defined Slc22a8 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.